By Katherine Hamilton
iPower said it restructured its supply chain to consolidate vendors and shift toward U.S.-based sourcing. Shares rallied 5% to $3.42 after closing down 3.3% on Friday.
Savara received priority review from the Food and Drug Administration for its application for Molbreevi. The stock rose 3.6% after closing down 3.3%.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 20, 2026 18:30 ET (23:30 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.